Colgate-Palmolive (CL) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Colgate-Palmolive (CL) reported $4.94 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 0.1%. EPS of $0.91 for the same period compares to $0.87 a year ago.The reported revenue represents a surprise of -0.86% over the Zacks Consensus Estimate of $4.99 billion. With the consensus EPS estimate being $0.89, the EPS surprise was +2.25%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Oral, Personal and Home Care- North America: $1.04 billion versus the six-analyst average estimate of $1.01 billion. The reported number represents a year-over-year change of +3.7%. Net Sales- Oral, Personal and Home Care- Latin America: $1.11 billion versus $1.11 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -7.2% change. Net Sales- Oral, Personal and Home Care- Africa/Eurasia: $269 million compared to the $261.71 million average estimate based on six analysts. The reported number represents a change of +2.7% year over year. Net Sales- Oral, Personal and Home Care- Europe: $668 million compared to the $687.89 million average estimate based on six analysts. The reported number represents a change of -2.5% year over year. Net Sales- Oral, Personal and Home Care- Asia Pacific: $724 million compared to the $724.34 million average estimate based on six analysts. The reported number represents a change of +3.7% year over year. Net Sales- Pet Nutrition: $1.14 billion versus the six-analyst average estimate of $1.17 billion. The reported number represents a year-over-year change of +2.3%. Net Sales- Total Oral, Personal and Home Care: $3.80 billion versus the six-analyst average estimate of $3.80 billion. The reported number represents a year-over-year change of -0.8%. Operating profit- Total Oral, Personal and Home Care: $969 million versus $1.03 billion estimated by four analysts on average. Operating profit- Corporate: -$179 million versus the four-analyst average estimate of -$184.13 million. Operating profit- Pet Nutrition: $275 million compared to the $256.82 million average estimate based on four analysts. View all Key Company Metrics for Colgate-Palmolive here>>>Shares of Colgate-Palmolive have returned +0.4% over the past month versus the Zacks S&P 500 composite's +2.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Colgate-Palmolive Company (CL): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks